Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07444268 · ClinicalTrials.gov registry record · Phase 1
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07444268 is a Phase 1 study that is actively recruiting participants, run by Sumitomo Pharma America. The registered enrollment target is 8 participants.
The verdict
NCT07444268, a Phase 1 study, is actively recruiting participants, sponsored by Sumitomo Pharma America.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
Interventions
- DRUG DSP-5336
- DRUG [14C]-DSP-5336
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07444268
The ClinicalTrials.gov registry entry for NCT07444268 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DSP-5336 is the first listed.
NCT07444268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07444268 about?
NCT07444268 is a clinical study titled "How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers". The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
What is the current status of trial NCT07444268?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2026-03-26. Estimated completion is 2026-08.
What interventions are being tested in trial NCT07444268?
The interventions under investigation include: DSP-5336 (DRUG), [14C]-DSP-5336 (DRUG).
Who is sponsoring clinical trial NCT07444268?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.